Cover Image
市場調查報告書

淋巴血管平滑肌肉增生症 - 開發平台分析

Lymphangioleiomyomatosis - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 246031
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
淋巴血管平滑肌肉增生症 - 開發平台分析 Lymphangioleiomyomatosis - Pipeline Review, H2 2014
出版日期: 2014年07月31日 內容資訊: 英文 41 Pages
簡介

淋巴血管平滑肌肉增生症是只發於女性,原因不明的罕見疾病。如同其名稱字面所示,是指肺部的淋巴腺、血管、以及氣管的平滑肌增生的疾病。特徵有發展性的呼吸困難、咳血、氣胸症、乳糜性肋膜積水,經過各種症狀後許多患者因呼吸不全而死亡。有時腹部與骨盆也會看見淋巴結,最多有50%的患者會產生腎臟血管肌肉脂肪瘤。

本報告提供淋巴血管平滑肌肉增生症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊,以及最新的新聞和發表。

簡介

  • 調查範圍

淋巴血管平滑肌肉增生症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • AstraZeneca PLC
  • Novartis AG
  • Circadian Technologies Limited
  • Therametrics holding AG
  • Nobelpharma Co., Ltd.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • sirolimus
  • everolimus
  • VGX-200 Series
  • DasKloster-0080-01
  • Small Molecule to Inhibit Src Tyrosine Kinase for Lymphangioleiomyomatosis

最近的開發平台趨勢

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5296IDB

Summary

Global Markets Direct's, 'Lymphangioleiomyomatosis - Pipeline Review, H2 2014', provides an overview of the Lymphangioleiomyomatosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lymphangioleiomyomatosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lymphangioleiomyomatosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lymphangioleiomyomatosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Lymphangioleiomyomatosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Lymphangioleiomyomatosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Lymphangioleiomyomatosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Lymphangioleiomyomatosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Lymphangioleiomyomatosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lymphangioleiomyomatosis Overview
  • Therapeutics Development
    • Pipeline Products for Lymphangioleiomyomatosis - Overview
    • Pipeline Products for Lymphangioleiomyomatosis - Comparative Analysis
  • Lymphangioleiomyomatosis - Therapeutics under Development by Companies
  • Lymphangioleiomyomatosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Lymphangioleiomyomatosis - Products under Development by Companies
  • Lymphangioleiomyomatosis - Companies Involved in Therapeutics Development
    • AstraZeneca PLC
    • Novartis AG
    • Circadian Technologies Limited
    • Therametrics holding AG
    • Nobelpharma Co., Ltd.
  • Lymphangioleiomyomatosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • sirolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VGX-200 Series - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DasKloster-0080-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Src Tyrosine Kinase for Lymphangioleiomyomatosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lymphangioleiomyomatosis - Recent Pipeline Updates
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Lymphangioleiomyomatosis, H2 2014
  • Number of Products under Development for Lymphangioleiomyomatosis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Lymphangioleiomyomatosis - Pipeline by AstraZeneca PLC, H2 2014
  • Lymphangioleiomyomatosis - Pipeline by Novartis AG, H2 2014
  • Lymphangioleiomyomatosis - Pipeline by Circadian Technologies Limited, H2 2014
  • Lymphangioleiomyomatosis - Pipeline by Therametrics holding AG, H2 2014
  • Lymphangioleiomyomatosis - Pipeline by Nobelpharma Co., Ltd., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Lymphangioleiomyomatosis Therapeutics - Recent Pipeline Updates, H2 2014

List of Figures

  • Number of Products under Development for Lymphangioleiomyomatosis, H2 2014
  • Number of Products under Development for Lymphangioleiomyomatosis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top